These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10271148)

  • 1. Post-patent barriers to entry in the pharmaceutical industry.
    Scherer FM
    J Health Econ; 1985 Mar; 4(1):83-7. PubMed ID: 10271148
    [No Abstract]   [Full Text] [Related]  

  • 2. Patent term extension: an expensive and unnecessary giveaway.
    Gore A
    Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692
    [No Abstract]   [Full Text] [Related]  

  • 3. Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry.
    McRae JJ; Tapon F
    J Health Econ; 1985 Mar; 4(1):43-61. PubMed ID: 10271145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of patent term restoration to small, high technology companies.
    Kiley TD
    Health Aff (Millwood); 1982; 1(2):46-52. PubMed ID: 7185722
    [No Abstract]   [Full Text] [Related]  

  • 5. Barriers to entry in the Canadian pharmaceutical industry. Comments, clarification and extensions.
    Gorecki PK
    J Health Econ; 1987 Mar; 6(1):59-72. PubMed ID: 10282730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From the molecule to the drug: innovation or distribution].
    Ménard HA
    Union Med Can; 1993; 122(1):4. PubMed ID: 8465475
    [No Abstract]   [Full Text] [Related]  

  • 7. Patent protection. Canadian drug firms boost R&D spending.
    Spurgeon D
    Nature; 1992 Feb; 355(6362):666. PubMed ID: 1741046
    [No Abstract]   [Full Text] [Related]  

  • 8. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 14. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 16. An economic assessment of patent settlements in the pharmaceutical industry.
    Dickey B; Orszag J; Tyson L
    Ann Health Law; 2010; 19(2):367-400, 2 p preceding i. PubMed ID: 21443148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

  • 18. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B
    BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
    [No Abstract]   [Full Text] [Related]  

  • 19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 20. [SCHWABE Company's patent portfolio of Ginkgo biloba preparation].
    Liu W; Cheng XM; Geng DM; Tan W; Zou WJ
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3384-8. PubMed ID: 25522634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.